Forte Biosciences
FBRX
FBRX was delisted on the 26th of August, 2026.
68 hedge funds and large institutions have $350M invested in Forte Biosciences in 2026 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 7 closing their positions.
408% more call options, than puts
Call options by funds: $3.09M | Put options by funds: $609K
171% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 7
15.95% more ownership
Funds ownership: 91.99% → 107.94% (+16%)
15% more funds holding
Funds holding: 59 → 68 (+9)
11% more capital invested
Capital invested by funds: $315M → $350M (+$35.7M)
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$28.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$17.8M |
| 3 |
Morgan Stanley
New York
|
+$12.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$6.72M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$4.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.3M |
| 2 |
Janus Henderson Group
London,
|
-$6.85M |
| 3 |
FAM
Fred Alger Management
New York
|
-$5.39M |
| 4 |
JG
Jain Global
New York
|
-$5.38M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$5.22M |
FBRX Hedge Fund Activity: Q1 2026 in Review
68 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q1 2026, worth a combined $350M — up 11% from $315M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new FBRX positions and 7 closed out — a net gain of 12 holders — while 21 added to existing stakes and 20 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $28.8M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $13.3M sold.
- 68 institutional investors held Forte Biosciences (FBRX) as of Q1 2026, up from 59 in Q4 2025.
- Funds reported $350M of Forte Biosciences stock for Q1 2026, up 11% quarter-over-quarter.
- 19 funds opened new Forte Biosciences positions in Q1 2026 and 7 closed out, a net change of +12 holders.
- The largest Forte Biosciences buyer in Q1 2026 was MPM BioImpact, an estimated $28.8M added.
- The largest Forte Biosciences seller in Q1 2026 was Point72 Asset Management, an estimated $13.3M sold.
Based on aggregated 13F filings for Q1 2026.